Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

BioBlast w/e 04 Aug 23

BioBlast w/e 04 Aug 23

03 AUG 2023 | US | Teva confirms intention to launch US adalimumab biosimilar AVT02 in 2024 Teva’s CEO confirmed that it will still pursue launching its Alvotech...

read more
BioBlast w/e 04 Aug 23

BioBlast w/e 28 Jul 23

27 JUL 2023 | EU | New indication alert: AZ’s Soliris® (eculizumab) approved to treat gMG in children aged six to 17 AstraZeneca announced that the EMA has approved Soliris®...

read more
BioBlast w/e 04 Aug 23

BioBlast w/e 21 Jul 23

21 JUL 2023 | EU | CHMP adopts positive opinion for three biosimilars The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

read more
BioBlast w/e 04 Aug 23

BioBlast w/e 14 Jul 23

14 JUL 2023 | EU | EMA confirms acceptance of Intas’ MAA for its ustekinemab (Stelara®) biosimilar Intas Pharmaceuticals announced that the European Medicine Agency (EMA) has...

read more
BioBlast w/e 04 Aug 23

BioBlast w/e 07 Jul 23

07 JUL 2023 | IN | CuraTeQ Biologics enters into exclusive licence agreement with BioFactura, Inc to commercialise its biosimilar to Janssen’s Stelara® (ustekinumab) Aurobindo...

read more
BioBlast w/e 04 Aug 23

BioBlast w/e 30 Jun 23

01 JUL 2023 | US | Organon and Samsung Bioepis announce launch of Hadlima®, biosimilar to AbbVie’s Humira® (adalimumab) Organon and Samsung Bioepis announced that Hadlima®,...

read more
BioBlast w/e 04 Aug 23

BioBlast w/e 23 Jun 23

22 JUN 2023 | JP | ASLAN enters strategic licence with Zenyaku Kogyo to exclusively develop and commercialise novel eblasakimab ASLAN Pharmaceuticals announced that it entered an...

read more
BioBlast w/e 04 Aug 23

BioBlast f/e 16 Jun 23

16 JUN 2023 | BR | Bio-Thera Solutions enter agreement for distribution of BAT2206 (ustekinumab biosimilar to Stelara®) in Brazil BusinessWire reports that Bio-Thera Solutions...

read more
Lexology

Recent BioBlast® Updates

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.